Theratechnologies Inc (TSE:TH) insider Christian Marsolais purchased 3,000 shares of Theratechnologies stock in a transaction dated Tuesday, July 18th. The stock was bought at an average cost of C$7.12 per share, for a total transaction of C$21,360.00.
Shares of Theratechnologies Inc (TSE:TH) traded up 1.55% on Monday, hitting $7.88. 52,238 shares of the stock traded hands. The firm’s 50-day moving average is $7.84 and its 200 day moving average is $6.04. Theratechnologies Inc has a 12-month low of $2.35 and a 12-month high of $8.72. The firm’s market cap is $586.39 million.
Several research analysts have commented on TH shares. National Bank Financial reiterated an “outperform” rating and set a C$7.15 price target on shares of Theratechnologies in a report on Thursday, May 4th. Canaccord Genuity reiterated a “speculative buy” rating and set a C$7.50 price target on shares of Theratechnologies in a report on Friday, May 5th. Finally, Scotiabank reiterated an “outperform” rating and set a C$9.50 price target on shares of Theratechnologies in a report on Wednesday, June 21st.
About Theratechnologies
Theratechnologies Inc is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy.
Receive News & Ratings for Theratechnologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.
